Gallbladder and biliary disease Several meta-analyses have found that GLP-1 agonists carry a modest increase in the risk of gallbladder or biliary disease (such as gallstones and cholecystitis), especially at higher doses, over longer durations, and when used mainly for weight loss [3]
doi: 10.1038/aps.2011.168, 59 HanssenR.RigouxL.KuzmanovicB.IglesiasS.KretschmerA
TAS is built to help organizations position ahead of where pressure is going next
So youll absolutely lose bone mass as well, he says
Similarly, our data indicate differential efficacy by ancestry (Supplementary Table 4), with GLP1 medications being most effective in people of European ancestry, less effective in people of Latino ancestry and least effective in people of African American ancestry
In May 2025, CVS Caremark announced that anti-obesity (AOM) tirzepatide (sold as Zepbound) would be removed from its preferred formulary effective July 1, 2025, with AOM semaglutide (sold as Wegovy) designated as the preferred alternative